Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
NEW YORK, May 02, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSE:IMUC) between May 1, 2012 and December 11, 2013. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/immunocellular-therapeutics-ltd
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which had engaged in stock promotion schemes.
If you suffered a loss in ImmunoCellular Therapeutics you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
